U.S. Markets closed
  • S&P 500

    3,845.08
    +13.69 (+0.36%)
     
  • Dow 30

    31,037.68
    +69.86 (+0.23%)
     
  • Nasdaq

    11,362.20
    +39.96 (+0.35%)
     
  • Russell 2000

    1,727.48
    -13.85 (-0.80%)
     
  • Crude Oil

    98.27
    -0.26 (-0.26%)
     
  • Gold

    1,738.10
    +1.60 (+0.09%)
     
  • Silver

    19.15
    -0.01 (-0.07%)
     
  • EUR/USD

    1.0188
    +0.0004 (+0.0407%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.82
    -0.72 (-2.61%)
     
  • GBP/USD

    1.1923
    +0.0002 (+0.0131%)
     
  • USD/JPY

    135.9910
    +0.0760 (+0.0559%)
     
  • BTC-USD

    20,554.44
    +361.22 (+1.79%)
     
  • CMC Crypto 200

    440.06
    +4.54 (+1.04%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LUND, Sweden, May 23, 2022 /PRNewswire/ -- The Pennsylvania and Maryland Departments of Health have granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory permits, allowing physicians in Pennsylvania and Maryland to order the IMMray™ PanCan-d test for their patients.

"Many clinicians in Pennsylvania and Maryland have been at the forefront of efforts to enhance surveillance for pancreatic cancer. We are very happy that these physicians can now utilize IMMray™ PanCan-d to detect pancreatic cancer in at-risk patients at stages 1 and 2. With these permits, we are now able to offer IMMray™ PanCan-d in 48 states," says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc., the US subsidiary of Immunovia AB.

For more information, please contact:

Philipp Mathieu

Acting CEO and President
Email: philipp.mathieu@immunovia.com

Tobias Bülow

Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74

The information was submitted for publication on May 23, 2022, at 08:30 am CET.

About Immunovia

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnos­tics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercializa­tion of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient ad­vocacy groups globally to make this test available to all high-risk pancreatic cancer groups.

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia--inc--market-access-increases-when-achieving-clinical-laboratory-permits-from-pennsylvania,c3572340

The following files are available for download: